The chromosomal translocation t(8;21) is associated with 10-15% of all cases of acute myeloid leukaemia (AML). The resultant fusion protein AML1/MTG8 interferes with haematopoietic gene expression and is an important regulator of leukaemogenesis. We studied the effects of small interfering RNA (siRNA)-mediated AML1/MTG8 depletion on global gene expression in t(8;21)-positive leukaemic cell lines and in primary AML blasts using cDNA arrays, oligonucleotide arrays and real-time reverse transcription-polymerase chain reaction (RT-PCR). Suppression of AML1/MTG8 results in the increased expression of genes associated with myeloid differentiation, such as AZU1, BPI, CTSG, LYZ and RNASE2 as well as of antiproliferative genes such as IGFBP7, MS4A3 and SLA both in blasts and in cell lines. Furthermore, expression levels of several genes affiliated with drug resistance or indicative of poor prognosis AML (BAALC, CD34, PRG2, TSPAN7) are affected by AML1/MTG8 depletion. In conclusion, siRNA-mediated suppression of AML1/MTG8 cause very similar changes in gene expression pattern in t(8;21)-positive cell lines and in primary AML blasts. Furthermore, the results suggest that the specific targeting of AML1/MTG8 function may be a promising approach for complementing existing treatment strategies.
Introduction
In acute myeloid leukaemia (AML), chromosomal aberrations prevalently affect transcription factor complexes controlling normal haematopoiesis. The heterodimeric core-binding factor complex (CBF) consisting of AML1 (RUNX1, CBFa2, PEBP2aB) and CBFb is most frequently targeted by such genetic lesions. AML1 is an essential haematopoietic transcription factor. Homozygous deletion of Aml1 is embryonic lethal because of a lack of definitive haematopoiesis (Okuda et al., 1996; Wang et al., 1996) .
The chromosomal translocation t(8;21)(q22;q22), which is observed in 10-15% of all AML cases, fuses the AML1 gene on chromosome 21 with the MTG8 (RUNX1T1, CBFA2T1, ETO, CDR) gene on chromosome 8, yielding a conserved chimaeric transcript (Erickson et al., 1992; Nisson et al., 1992; Miyoshi et al., 1993) . In the resulting AML1/MTG8 fusion protein, the N-terminal part of AML1, containing the DNA-binding domain, the RUNT domain, is fused to the almost complete MTG8 sequence. MTG8 is part of a repressor complex also containing PLZF (Melnick et al., 2000) , and interacts via N-CoR and SIN3A with histone deacetylases (HDACs) 1, 2 and 3 (Gelmetti et al., 1998; Lutterbach et al., 1998; Wang et al., 1998; Amann et al., 2001; Hildebrand et al., 2001) . In contrast to the closely related genes MTGR1 and MTG16 (ETO2), MTG8 is not expressed in myeloid progenitor cells (Miyoshi et al., 1993; Morohoshi et al., 2000) .
AML1/MTG8 interferes with haematopoietic transcription by recruiting HDACs to AML1-responsive promoters leading to histone deacetylation and transcriptional silencing of genes such as CSF1R (c-fms), CSF2RA (GM-CSFRa) or p14 ARF (Frank et al., 1995; Linggi et al., 2002; Follows et al., 2003) . Notably, introduction of AML1/MTG8 into one Aml1 allele resulted in a phenotype very similar to the one obtained by homozygous inactivation of Aml1, again suggesting that AML1/MTG8 acts as a transdominant repressor of AML1 functions (Yergeau et al., 1997) . In addition, AML1/MTG8 binds and inhibits a variety of transcription factors relevant for myeloid differentiation Jakubowiak et al., 2000; Pabst et al., 2001; Puccetti et al., 2002; Vangala et al., 2003; Zhang et al., 2004) .
The phenotypic consequences of AML1/MTG8 expression depend very much on the cellular context. For instance, ectopic AML1/MTG8 expression inhibits myeloid differentiation, but also induces apoptosis in leukaemic cell lines such as U937 (Burel et al., 2001) . However, AML1/MTG8 supports the expansion of haematopoietic progenitor cells both ex vivo and in vivo by enhancing their self-renewal and, at least in some studies, by interfering with their maturation Rhoades et al., 2000; Mulloy et al., 2002; Tonks et al., 2003; Baesecke et al., 2005) . Nevertheless, AML1/MTG8 alone is not sufficient to induce leukaemia in murine model systems. Furthermore, AML1/ MTG8 expression was found in cord blood at a 100-fold higher frequency than the risk to develop AML, and in AML patients in long-term remission (Kusec et al., 1994; Miyamoto et al., 2000; Mori et al., 2002) .
We examined the functions of endogenously expressed AML1/MTG8 in terminally developed leukaemic cells using small interfering RNAs (siRNAs). siRNA-mediated transient depletion of AML1/MTG8 restored myeloid differentiation, inhibited leukaemic clonogenicity and proliferation, and induced a senescence-associated cell cycle arrest (Heidenreich et al., 2003; Martinez et al., 2004) . Thus, despite its inability to drive leukaemogenesis by its own, AML1/MTG8 seems to be essential for maintaining the leukaemic phenotype.
In the current study, we used siRNAs to directly examine AML1/MTG8-dependent changes in gene expression in both t(8;21)-positive leukaemic cell lines and in primary blasts. We show that siRNA-mediated depletion of AML1/MTG8 results in an expression pattern suggesting the onset of myeloid differentiation and inhibition of leukaemic proliferation.
Results
To examine AML1/MTG8-dependent changes in gene expression, we transfected t(8;21)-positive leukaemic Kasumi-1 cells either with AML1/MTG8 siRNA (siAGF1) or with a mismatch control siRNA (siAGF6). The siRNA-mediated AML1/MTG8 depletion was validated by immunoblot analysis. In comparison to the mismatch control siAGF6, siAGF1 caused a substantial decrease in AML1/MTG8 protein without affecting the amount of mutated p53, which served as a loading control (Figure 1a ) (Banker et al., 1998) . siRNA-mediated depletion of AML1/MTG8 caused a twofold increased expression of p14 ARF (Figure 1b) , an established target gene of AML1/MTG8 (Linggi et al., 2002) . Furthermore, transcript levels of the indirect target gene C/EBPa were also raised twofold (Figure 1c ) Pabst et al., 2001) . Moreover, AML1/MTG8 depletion was associated with a twofold increase in Sudan black-positive cells ( Figure 1d ) and a decrease in CD34 surface expression (Martinez et al., 2004) , thus indicating myeloid differentiation.
Four days after a single siRNA treatment, total RNA was isolated and subjected to global gene expression analysis using a human Unigene chip containing 4608 Figure 1 siRNA-mediated depletion of AML1/MTG8 suppression in Kasumi-1 cells. (a) AML1/MTG8 suppression in Kasumi-1 cells. Total protein was isolated 4 days after siRNA electroporations. AML1/MTG8 was detected with an antibody targeting the C-terminus of MTG8. Length standard is shown on the right. p53 served as a loading control. (b) Transfection with AML1/MTG8 siRNA induces p14 ARF expression. Total RNA was isolated 4 days after siRNA electroporations. Error bars indicate standard deviations. (c) AML1/MTG8 depletion raises C/EBPa transcript levels. Total RNA was isolated 4 days after siRNA electroporations. Error bars indicate standard deviations. (d) AML1/MTG8 suppression increases the number of Sudan black-positive Kasumi-1 cells. Cells were stained with Sudan black 4 days after siRNA transfection. Original magnification was 100-fold. siAGF1 and siAM, AML1/MTG8 siRNAs; siAGF6, mismatch control siRNA; siGL2, sequence-unrelated control siRNA. different cDNAs. We performed two independent experiments with two arrays per experiment. Selection criteria were an at least twofold changed expression in combination with a ratio between average change and the corresponding standard deviation of at least 2. Applying these criteria, 40 genes were identified with changed expression levels upon AML1/MTG8 depletion (Table 1) . Twenty-eight genes were up regulated and 12 genes were downregulated.
In a second set of experiments, we employed oligonucleotide arrays to identify genes affected by the AML1/MTG8 status. In this case, Kasumi-1 cells were either mock transfected or transfected with AML1/ MTG8 siRNA, with a mismatch control siRNA, or with a sequence-unrelated siRNA targeting green fluorescent protein (GFP) mRNA. Total RNA was isolated 4 days after transfection as in the previous set of experiments, and subjected to oligonucleotide array analysis with two arrays used for RNA from siAGF1-treated cells, and one array for each of the other samples. Genes considered to show substantially changed expression upon AML1/MTG8 depletion had to fulfil the following requirements: expression levels had to change at least twofold when compared to each of the controls. Furthermore, the expression changes had to be larger than the difference of expression levels between the two chips used for AML1/MTG8-suppressed cells. Forty-six genes fulfilled these criteria, with 36 genes showing increased expression levels, and 10 genes showing decreased expression levels upon AML1/MTG8 depletion including MTG8 (RUNX1T1, twofold down). As MTG8 itself is not expressed in Kasumi-1 cells (Miyoshi et al., 1993) , and since the AML1/MTG8 fusion transcript should hybridize with the MTG8 probes on the array, this change reflects the siRNA-mediated reduction of AML1/MTG8 transcript levels ( Table 2) .
AML1/MTG8 depletion affected several transcription factor genes (BTG1, ELK3, ID1, FOSL2, IFI16, MEF2C, NFE2), genes involved in signal transduction (ATP2B4, CXCR4, DEPDC6, DUSP6, IGFBP7, LAPTM5, MS4A3, PSTPIP, RASGRP2, SLA), and genes associated with cell morphology, adhesion and migration (ADAM12, CD34, CKLSF3, EDIL3, GCA, ICAM3, LCP1, MTSS1, MYO1F, S100A8, SELPLG). Furthermore, expression levels of several genes linked with drug resistance or poor clinical prognosis (AZU1, BAALC, CD34, PRG2, RNASE2, TSPAN7) changed upon AML1/MTG8 suppression. Fourteen genes (AZU1, BPI, BTG1, CD24, CTSG, DUSP6, ELK3, ICAM3, IFI16 IGFBP7, LAPTM5, LYZ, NKG7, SLA) affected by AML1/MTG8 depletion were identified by both cDNA array and oligonucleotide array analysis (Figure 2 ). Moreover, 35 out of 45 genes showed an at least 1.3-fold change in each array analysis indicating a substantial extent of agreement (data not shown). Importantly, transcript levels of genes associated with interferon responses such as OAS genes, interferon genes or STAT1 were not affected by AML1/MTG8 depletion (data not shown). None of the siRNAs used interfered with the expression of wild-type AML1 (data not shown), further demonstrating the specificity of the AML1/MTG8 siRNA approach.
To validate observed changes in gene expression, we repeated the siRNA treatment of Kasumi-1 cells followed by RNA isolation and subsequent realtime reverse transcription-polymerase chain reaction (RT-PCR) analysis. We examined the transcript levels of 38 genes suggested by gene expression profiling to be affected by AML1/MTG8 depletion. Changes in transcript levels were confirmed for 32 genes (Figure 3 ). Twelve of those confirmed genes (AZU1, BPI, CD24, CTSG, DUSP6, ELK3, ICAM3, IGFBP7, LAPTM5, LYZ, NKG7, SLA) showed substantial AML1/MTG8-dependent changes in expression in all three analyses (cDNA array analysis, oligonucleotide array analysis, real-time PCR analysis). Abbreviations: AML, acute myeloid leukaemia; si, small interfering. Changes in expression levels are shown as ratios between cells treated with active siRNA (siAGF1) and cells treated with control siRNA (siAGF6). Genes also found to be affected by oligonucleotide array analysis of AML1-MTG8-depleted Kasumi-1 cells are shown in bold, genes changed both in AML1/MTG8-depleted Kasumi-1 cells and AML blasts are underlined.
Next, we asked whether the AML1/MTG8-dependent changes in transcript levels are common to t(8;21) leukaemic cells, or if they are specific for Kasumi-1 cells. We chose 14 different genes and examined the corresponding transcript levels in siRNA-treated t(8;21)-positive SKNO-1 cells by real-time PCR (Figure 4) . Six of these genes (BPI, CTSG, IGFBP7, LAPTM5, NKG7, SLA) exhibited at least twofold changes in transcript levels after siRNA-mediated AML1/MTG8 depletion. One of the genes showing no significant change in expression upon AML1/MTG8 depletion was ID1, which could also not be confirmed in Kasumi-1 by RT-PCR. The expression levels of five genes (BAALC, CD24, DUSP6, GCA, IL6R) changed less than twofold after siRNA treatment of SKNO-1 cells, but showed the same tendency as in siRNA-treated Kasumi-1 cells.
We also examined global expression patterns in t(8;21)-positive AML blasts treated with either AML1/ MTG8 siRNA or mismatch siRNA. RT-PCR analysis confirmed a twofold decrease in AML1/MTG8 transcript levels upon treatment with siAGF1 (data not shown). Thirty-seven genes showed an at least threefold increased transcript level upon AML1/MTG8 depletion (Table 3) . Electroporation with AML1/ MTG8 siRNA increased the expression of 12 genes (AZU1, CD24, CST7, GCA, IGFBP7, MS4A3, NKG7, NUCB2, PLAC8, PRG2, RNASE2, S100A8) both in Kasumi-1 cells and in AML blasts. Moreover, siRNA treatment of blasts obtained from a second patient suffering from t(8;21)-positive AML reduced AML1/ MTG8 mRNA levels twofold in comparison to AML1 (RUNX1, data not shown) and increased transcript levels of BPI, CTSG and IGFBP7 4.6-fold, threefold and 2.4-fold, respectively ( Figure 5 ). Thus, in addition to the genes identified by array analysis, BPI and CTSG may also be affected by AML1/MTG8 suppression in primary AML blasts. Moreover, the substantial overlap of AML1/MTG8-regulated genes strongly suggests that siRNA-mediated AML1/MTG8 depletion has similar consequences for both t(8;21)-positive cell lines and primary leukaemic blasts.
As siRNAs may affect gene expression of unintended targets with rather limited homology, we examined possible off-target effects of AML1/MTG8 siRNA. Therefore, we transfected the t(8;21)-negative leukaemic cell line U937 either with AML1/MTG8 siRNA or with Immune response 2.2-2.9 3.0-3.9 2.6-3.7
Abbreviations: AML, acute myeloid leukaemia; GFP, green fluorescent protein; si, small interfering. Changes in expression levels are shown as ratios between cells treated with active siRNA (siAGF1) and cells treated with control siRNAs (siAGF6, siGFP), or mocktransfected cells. Genes also found to be affected by cDNA array analysis of AML1-MTG8-depleted Kasumi-1 cells are shown in bold, genes changed both in AML1/MTG8-depleted Kasumi-1 cells and AML blasts are underlined. Identification of AML1/MTG8-affected genes J Dunne et al mismatch control siRNA ( Figure 6 ). Notably, none of the examined genes showed a substantially changed expression level upon transfection with AML1/MTG8 siRNA, indicating that the observed changes in siRNAtreated t(8;21)-positive cells are a consequence of AML1/MTG8 depletion, and are not caused by offtarget effects of the AML1/MTG8 siRNA. BPI and ELA2 were the only genes affected by AML1/MTG8 expression with an established functional AML1 binding site in their promoters (Lennartsson et al., 2003; Lausen et al., 2006) . To identify possible AML1 (and therefore AML1/MTG8) binding sites in the promoters of other genes influenced by AML1/ MTG8 depletion, we inspected selected genes for occurrence of the TGYGGT consensus sequence in regions upstream of the start of transcription (Meyers et al., 1993) . For instance, the IGFBP7 gene contains six possible binding sites and the SLA gene four possible binding sites for AML1/MTG8 within the 2 kb region preceding the start of transcription. Next, we examined intracellular binding of AML1/MTG8 by chromatin immunoprecipitation (ChIP) assays. To isolate specifically DNA sequences bound by AML1/MTG8, a tandem affinity purification (TAP)-tagged version of this fusion protein was ectopically expressed in U937 cells. As a control, we used non-transfected U937. The c-FOS promoter served as a further negative control. ChIP showed that not only BPI but also IGFBP7 and SLA promoter sequences were bound by TAP-tagged AML1/MTG8 (Figure 7) . In contrast, c-FOS promoter sequences could not be precipitated, indicating the absence of any in vivo interaction with AML1/MTG8. Furthermore, none of the sequences could be precipitated from lysates derived from control-transfected U937 cells. In conclusion, these data suggest that AML1/MTG8 binds directly to upstream sequences of the BPI, IGFBP7 and SLA genes. This finding in combination with the observed increase of expression Identification of AML1/MTG8-affected genes J Dunne et al upon AML1/MTG8 depletion implies that at least these three genes may be direct target genes for AML1/ MTG8.
Discussion
We addressed the role of AML1/MTG8 in both t(8;21)-positive cell lines and in patient blast cells by inhibiting its endogenous expression with siRNAs followed by gene expression profiling. In total, we identified 76 genes with changes in expression levels upon AML1/MTG8 depletion.
We have previously shown that AML1/MTG8 siRNAs facilitate tumour growth factor b/vitamin D 3 -induced differentiation in the t(8;21)-positive cell lines Kasumi-1 and SKNO-1 (Heidenreich et al., 2003) . In agreement with this observation, suppression of AML1/ MTG8 results in a gene expression pattern indicative of myeloid differentiation. For instance, AML1/MTG8 depletion inhibits the expression of CD34, a marker for haematopoietic stem and early progenitor cells. Furthermore, expression of several genes associated with the formation of azurophil granules (AZU1, BPI, CTSG, ELA2, LYZ, PRTN3) is raised upon AML1/MTG8 suppression suggesting the onset of granulocytic differentiation during the transition from the myeloblastic to the promyelocytic stage (Weiss and Olsson, 1987; Zimmer et al., 1992; Garwicz et al., 2005) . An initiation of myeloid differentiation is further indicated by increased expression levels of genes such as CD24, GCA, NKG7 (GIG1), NFE2, PRG1, PRG2, RNASE2, RNASE3 or S100A8 (MRP8).
In addition to initiating myeloid differentiation, AML1/MTG8 depletion affects leukaemic clonogenicity and proliferation, and irreversibly arrests Kasumi-1 cells in the G1 phase of the cell cycle (Martinez et al., 2004) . Several genes with increased expression levels upon AML1/MTG8 siRNA treatment (BTG1, IGFPB7, MS4A4, NFE2, SLA) have previously been shown to inhibit cellular proliferation. For instance, IGFBP7 (IGFBP-rP1, MAC25) binds to insulin and insulinlike growth factor 1, thereby inhibiting proliferation (Oh et al., 1996; Yamanaka et al., 1997) . Interestingly, IGFBP7 expression is downregulated in several types of cancer, and restoration of its expression induces cellular senescence or apoptosis (Swisshelm et al., 1995; Lopez-Bermejo et al., 2000; Landberg et al., 2001; Mutaguchi et al., 2003) . The transmembrane protein MS4A3 (HTm4) inhibits G1-S cell cycle transition in haematopoietic cells by binding to cyclin-dependent kinase (CDK)-associated phosphatase-CDK2 complexes (Donato et al., 2002) . The Src-like adaptor protein SLA inhibits NIH3T3 proliferation by blocking the Src binding site of platelet-derived growth factor receptor (Roche et al., 1998) , and impairs erythropoietin (Epo)-induced erythroblast survival by binding to Epo receptor (Lebigot et al., 2003) . In conclusion, AML1/ MTG8 may support leukaemic proliferation by directly or indirectly downmodulating the expression of antiproliferative genes.
Importantly, we observed similar changes in expression pattern upon AML1/MTG8 depletion in both Kasumi-1 and in t(8;21)-positive AML blasts. Both cell systems react to AML1/MTG8 suppression by increased expression of differentiation-associated and antiproliferative genes. Furthermore, both cell types share 12 genes with increased transcript levels after the application of AML1/MTG8 siRNA, but not of control siRNAs. This similarity between cell lines and primary patient material supports the relevance of the cell culture model for AML with t(8;21). Furthermore, it strongly suggests that directly and specifically targeting AML1/ MTG8 may be of benefit for patients suffering from t(8;21)-associated AML.
The effects of AML1/MTG8 on global gene expression have also been examined by its ectopic expression in t(8;21)-negative leukaemic cell lines. In two studies, AML1/MTG8 expression was induced in the monoblastic cell line U937 (Alcalay et al., 2003; Fliegauf et al., 2004) . Interestingly, ectopic AML1/MTG8 expression inhibited the expression of four genes (LCP1, LYZ, NFE2, SLA), which are induced upon siRNA-mediated AML1/MTG8 depletion. Recently, Cammenga and Nimer made the results of a gene array study in the NCBI GEO database available (Barrett et al., 2005) , where they examined the consequences of ectopic AML1/MTG8 expression in human CD34 þ cells isolated from peripheral blood (Accession no. GSE2049) (Mulloy et al., 2005) . Interestingly, 34 genes found by us to be affected in Kasumi-1 cells by AML1/MTGT8 siRNAs were also detected in their analysis (Table 4) . Abbreviations: AML, acute myeloid leukaemia; GFP, green fluorescent protein; si, small interfering. Changes in expression levels are shown as ratios between cells treated with active siRNA (siAGF1) and cells treated with control siRNA (siAGF6). Genes found to be affected by cDNA and oligonucleotide array analysis of AML1-MTG8-depleted Kasumi-1 cells are shown in bold, genes changed both in AML1/MTG8-depleted Kasumi-1 cells and AML blasts are underlined.
Figure 5 AML1/MTG8-dependent gene expression in primary AML blasts. Expression levels were normalized to GAPDH expression. Expression levels were calculated as indicated in Figure 3 . Relative expression levels are shown on a log 2 scale. Error bars indicate standard deviations.
Identification of AML1/MTG8-affected genes J Dunne et al
In each case, ectopic expression of AML1/MTG8 in CD34 þ cells showed the opposite effect on expression levels when compared to the consequences of siRNAmediated AML1/MTG8 suppression. Moreover, for 16 out of 20 genes also detected in AML1/MTG8-depleted AML blasts opposite changes in expression levels were noted. This remarkable agreement between these two studies strongly suggests that at least this subset of genes is directly or indirectly affected by AML1/MTG8. Different leukaemic fusion proteins such as AML1/ MTG8 or PML-RARa interfere with common biologic processes such as differentiation and proliferation.
In this context, several genes are repressed by either of these fusion products when ectopically expressed in U937 cells (Alcalay et al., 2003) . We identified two of these genes, NFE2 and CSF3R, to be repressed by AML1/MTG8 in Kasumi-1 cells. Moreover, MLL, whose gene is frequently targeted by chromosomal rearrangements, has been found to associate with six (BPI, CD24, CST7, GCA, NKG7, S100A8) out of 
Abbreviations: AML, acute myeloid leukaemia; D, decreased; I, increased; NS, not substantially changed. Array data for AML1/ MTG8-depleted cells are shown in the second and third column, data for AML1/MTG8-transduced CD34 + cells from peripheral blood are shown in the fourth column (GEO Accession no. GSE2049, Cammenga and Nimer 2005).
Identification of AML1/MTG8-affected genes J Dunne et al 14 genes affected by AML1/MTG8 depletion in both t(8,21)-positive leukaemic cell lines and AML blasts (Guenther et al., 2005) . Thus, AML1/MTG8-mediated regulation of these genes might, at least in part, depend on MLL. Moreover, these genes may also be affected by, for instance, MLL-AF9 or MLL-ENL, indicating an intersection of genes and associated cellular processes as common targets for these aberrant transcriptional regulators.
Comparison of AML1/MTG8-affected genes with gene expression profiles obtained for AML patient material identifies two groups of genes common to both approaches (Table 5 ). One group consists of genes with expression levels typical for CBF leukaemias, including t(8;21)-positive AMLs. Application of AML1/MTG8 siRNA reduced the expression of those genes (BAALC, CBFA2T1, CD34, DUSP6) with an elevated expression in leukaemic cells, and increased transcript levels of those (ATP2B4, LAPTM5, LCP1) with diminished expression in blast cells (Yagi et al., 2003; Bullinger et al., 2004; Ross et al., 2004; Valk et al., 2004) . A second group (CALR, CST7, HGF, IGFBP7, MEF2C, NKG7, PRG1 and RNASE3) contains genes with increased expression levels in t(15;17)-positive acute promyelocytic leukaemia (APL) or in mainly monocytic AMLs with 11q23 abnormalities (Table 5 ). Treatment of t(8;21)-positive cells with AML1/MTG8 siRNA also raised the expression levels of these genes. As APL and monocytic AMLs represent more differentiated subtypes of AML than t(8;21)-associated AMLs, these concordant changes in expression can be explained by the onset of myeloid differentiation upon AML1/ MTG8 depletion.
High expression of BAALC as well as low expression of either AZU1, PRG2 or RNASE2 correlate with a poor treatment outcome of AML (Baldus et al., 2003a, b; Bullinger et al., 2004; Valk et al., 2004) . The leukaemic cell lines Kasumi-1 and SKNO-1 have been isolated from patients suffering from, and finally succumbing to, leukaemic relapse (Asou et al., 1991; Matozaki et al., 1995) . Interestingly, transfection of these leukaemic cell lines with AML1/MTG8 siRNAs inhibited BAALC expression and enhanced the expression of AZU1, PRG2 and RNASE2 (Table 5) . Furthermore, expression of CD34 and TSPAN7 (TM4SF2), which correlates with drug resistance (Bullinger et al., 2004; Heuser et al., 2005) , is diminished in AML1/ MTG8-depleted Kasumi-1 cells (Table 5 ). These findings suggest that AML1/MTG8 suppression or inhibition of its function may enhance drug sensitivity of t(8;21)-positive leukaemic cells, and might improve the outcome of t(8;21)-positive leukaemia patients.
In summary, we show that siRNA-mediated suppression of AML1/MTG8 results in a gene expression pattern indicative of myeloid differentiation paired with a compromised leukaemic proliferation in both leukaemic cell lines and primary AML blasts. These results allude to a central role for this fusion gene in these two processes, and suggest that AML1/MTG8 is essential for the maintenance of t(8;21)-positive AML.
Materials and methods

Cell culture
Kasumi-1 cells (Asou et al., 1991) and U937 cells (Sundstrom and Nilsson, 1976) were cultured in RPMI1640 containing 10% fetal calf serum (FCS). SKNO-1 cells (Matozaki et al., 1995) were maintained in RPMI1640 supplemented with 20% FCS and 7 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF). Primary t(8;21)-positive AML blasts were cultured in Iscove's modified Dulbecco's medium (Invitrogen, Karlsruhe, Germany) containing 20% Stemspan BIT 9500 plus 20 ng/ml interleukin (IL)-3, IL-6, granulocyte colonystimulating factor, GM-CSF, 50 ng/ml stem cell factor (Preprotech, London, UK).
Patients
The leukaemia sample used for the oligonucleotide array analysis (Table 3) was obtained from bone marrow of a 52-year-old male patient with AML FAB M2 in St Bartholomew's Hospital. Mononuclear cells were purified from white blood cells and neutrophils by Ficoll-Hypaque densitygradient centrifugation. The sample was frozen in liquid nitrogen with 10% dimethyl sulphoxide in FCS. The karyotype was 46, XY, del(7)(q32q36), t(8;21)(q22;q22). Bone marrow blasts used for RT-PCR detection ( Figure 5 ) were isolated from a 67-year-old male patient with AML FAB M2 subtype by Ficoll-Isopaque density-gradient centrifugation. siRNA transfections Kasumi-1 cells and AML blasts were transfected with the indicated siRNA concentrations using a Fischer EPI 3500 electroporator (Fischer, Heidelberg, Germany) as described previously (Martinez et al., 2004) . The following siRNAs were used: AML1/MTG8 siRNAs siAGF1 (sense, 5 0 -CCU CGA AAU CGU ACU GAG AAG-3 0 ; antisense, 5 0 -UCU CAG UAC GAU UUC GAG GUU-3 0 ) and siAM (same target site as siAGF1, contains dT 3 0 -overhangs; sense, 5 0 -CCU CGA AAU CGU ACU GAG AdTdT-3 0 ; antisense, 5 0 -UCU CAG UAC GAU UUC GAG GdTdT-3 0 ), mismatch control siAGF6 (sense, 5 0 -CCU CGA AUU CGU UCU GAG AAG-3 0 ; antisense, 5 0 -UCU CAG AAC GAA UUC GAG GUU-3 0 ), unrelated sequence control siGL2 (sense, 5 0 -CGU ACG CGG AAU ACU UCG AdTdT-3 0 ; antisense, 5 0 -UCG AAG UAU UCC GCG UAC GdTdT-3 0 ), unrelated sequence control siRNA siGFP (sense, 5´-GCA AGC UGA CCC UGA AGU UCA U-3 0 ; antisense, 5 0 -GAA CUU CAG GGU CAG CUU GCC G-3 0 ).
RNA and protein isolation
If not indicated otherwise, total RNA was isolated 4 days after siRNA electroporation using RNeasy columns (Qiagen, Hilden, Germany). Total protein was precipitated by adding two volumes of acetone to the flow through of the RNeasy columns and resuspended in urea buffer (9 M urea, 4% (w/w)
cDNA microarrays cDNA microarrays containing 4608 different cDNAs spotted twice were generated using an Affymetrix 417 Arrayer (Affymetrix, St Clara, CA, USA). Total RNA (50 mg) were 
TCCCAGTTAATTGGCATGCTG TCATACTGATTGGCCGTGATG
Identification of AML1/MTG8-affected genes J Dunne et al used to synthesize Cy3-and Cy5-labeled cDNAs according to published protocols (http://brownlab.stanford.edu). Microarray experiments and analyses including standardization and quality control were performed as described (Berwanger et al., 2002) .
Oligonucleotide arrays RNA isolation, labelling and hybridization onto HGU133_Plus2 Gene chip arrays (Affymetrix, St Clara, CA, USA) were performed as described (Debernardi et al., 2003) . Bioconductor was used to calculate the level of expression for each gene (Gentleman et al., 2004) . The data were normalized by quantile normalization as implemented in the affymetrix package of Bioconductor. All the statistical analysis was done with R (http://www.R-project.org). Empirical Bayesian methodology, as implemented in the EBarrays package of Bioconductor, was used and leads to shrinkage estimates of fold changes. Genes were identified as differentially expressed with the assumption of the Log-Normal model of gene expression.
Real-time RT-PCR and immunoblotting
Real-time RT-PCR analyses were performed as described (Martinez et al., 2004) . Primer sequences are shown in Table 6 . Immunoblotting was performed as described (Martinez et al., 2004) . The following antibodies were used: AML1/MTG8, ETO C-20 (sc-9737; Santa Cruz Biotechnology, Heidelberg, Germany; 1:1000); p53 Bp53-12 (sc-263; Santa Cruz Biotechnology, Heidelberg, Germany; 1:5000) and tubulin Ab-4 (1 mg/l, MS-719-P0; NeoMarkers, Fremont, CA, USA).
Chromatin immunoprecipitation U937 cells were electroporated with pNTAPRC1 encoding a TAP-tagged AML1/MTG8 under the control of a cytomegalovirus promoter (Philippar et al., 2004) . ChIP assays were performed using the ChIP assay kit according to the manufacturer (Upstate, Lake Placid, NY, USA) with the following modifications. TAP-AML1/MTG8 complexes were isolated using immunoglobuline G sepharose 6 fast flow beads (Amersham Biosciences, Freiburg, Germany). Eluted DNA fragments were amplified by PCR, separated by agarose gel electrophoresis and visualized by ethidium bromide staining. The primers for BPI (forward, 5 0 -CCA CCC ACC TTC AAG GGA GT-3 0 ; reverse, 5 0 -TCC ATT GTG GTT AGG GCC C-3 0 ), c-fos (forward, 5 0 -CTC TCA GAG TCG CGG TCT GAC-3 0 ; reverse, 5 0 -CGA CCC TTC CCC CCA TAT AA-3 0 ), IGFBP7 (forward, 5 0 -CAG GAG TTT GAG ACC AGC CTG-3 0 ; reverse, 5 0 -CTC CCT GTG TCG CCT AGT CTG-3 0 ) and SLA (forward, 5 0 -TTT GCG AGC CTG GTC ATT G-3 0 ; reverse, 5 0 -TTG AGG GAG GTC TGC ACT GC-3 0 ) were designed with the Primer Express software (Applied Biosystems, Foster City, CA, USA).
